MARKET

ZFGN

ZFGN

Zafgen
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.090
-0.130
-10.66%
After Hours: 1.130 +0.04 +3.67% 16:21 02/27 EST
OPEN
1.220
PREV CLOSE
1.220
HIGH
1.220
LOW
1.060
VOLUME
171.35K
TURNOVER
--
52 WEEK HIGH
4.990
52 WEEK LOW
0.6200
MARKET CAP
40.74M
P/E (TTM)
-0.7704
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ZFGN and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ZFGN stock price target is 0.7800 with a high estimate of 0.7800 and a low estimate of 0.7800.

EPS

ZFGN News

More
  • 5 Deep-Value Stocks for 2020
  • GuruFocus.com · 12/30/2019 19:26
  • The Daily Biotech Pulse: Seattle Genetics' Bladder Cancer Drug Gets FDA Nod, Paratek Wins Contract For Antibiotic
  • Benzinga · 12/19/2019 12:52
  • The Daily Biotech Pulse: Seattle Genetics' Bladder Cancer Drug Gets FDA Nod, Paratek Wins Contract For Antibiotic
  • Benzinga · 12/19/2019 12:52
  • Zafgen and Chondrial Therapeutics Announce Definitive Merger Agreement; Zafgen Shareholders to Own 40% of Combined Co
  • Benzinga · 12/18/2019 11:02

Industry

Biotechnology & Medical Research
-2.78%
Pharmaceuticals & Medical Research
-2.83%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About ZFGN

Zafgen, Inc., is a clinical-stage biopharmaceutical company. The Company uses its proprietary methionine aminopeptidase 2 (MetAP2) biology platform to develop novel therapies for patients affected by complex metabolic diseases. Its product candidate is ZGN-1061 which is a novel fumagillin-class MetAP2 inhibitor that is used to treat type 2 diabetes and other related metabolic disorders. Type 2 diabetes is a prevalent, chronic, progressive and multifactorial disorder that leads to increased microvascular and macrovascular disease and as such increases risk of death from cardiovascular disease, stroke, and kidney failure. Its MetAP2 development candidate ZGN-1258 is administered by subcutaneous injection. ZGN-1258 is used for the treatment of Prader-Willi syndrome (PWS). PWS is a rare and complex genetic disorder characterized by physiologic, cognitive and behavioral symptoms including hyperphagia, uncontrollable hunger and its related behaviors, and obesity.
More

Webull offers kinds of Zafgen Inc stock information, including NASDAQ:ZFGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZFGN stock news, and many more online research tools to help you make informed decisions.